Clinical trials
Refractory Hematologic Malignancy clinical trials
Below are recruiting refractory hematologic malignancy clinical trials, each written for real people, not researchers. We’re tracking 123 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07572006RecruitingPhase 1
Study of JNJ-95804306 for blood cancers that returned or didn't respond
This trial tests a new drug called JNJ-95804306 for people with certain blood cancers (like acute myeloid leukemia, myelodysplastic syndromes, or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. The goal is to see if the drug is safe and if it can help.
Indianapolis, IndianaAges 18 years+ - NCT04515810Recruiting
Mobile app coaching for planning care after serious cancer
This study tests a mobile health app (PACT) to help people with advanced cancer talk and plan for future care. It may help you and a loved one stay engaged in advance care planning (planning what care you want and who should speak for you).
Manhasset, New YorkAges 18 years+ - NCT04283006RecruitingEarly Phase 1
CAR T-cell treatment for hard-to-treat B-cell blood cancers
This early-phase trial tests a special kind of immune cell treatment (CAR T cells) that targets CD20 and CD22 in people with relapsed or refractory B-cell cancers. It may help by attacking cancer cells that survived prior treatments, but it is still being studied for safety and early effectiveness.
Hangzhou, ZhejiangAges 3–70 - NCT05110742RecruitingPhase 1/Phase 2
CD5-targeting NK cell therapy for blood cancers
This trial tests a new kind of immune cell therapy (NK cells) that are made to attack cancer cells carrying the CD5 marker. You will have a short course of chemotherapy before the infusion to help the cells work. It is for people with certain blood cancers that have not responded to standard treatments.
Houston, TexasAges 18 years+ - NCT07285668Recruiting
Special donor immune cells after stem cell transplant for high-risk blood cancers
This study tests whether giving specially treated donor immune cells after a stem cell transplant can help prevent relapse in patients with high-risk blood cancers. You would get a stem cell transplant from a relative, followed by an infusion of donor cells that have been processed to reduce the risk of graft-versus-host disease.
Madison, WisconsinAges 18–80 - NCT03328078RecruitingPhase 1/Phase 2
Emavusertib for recurrent brain lymphoma after prior treatment
This Phase 1/2 trial tests emavusertib (a targeted medicine) in adults with primary central nervous system lymphoma that has come back or not responded to treatment. It’s designed to find safe dosing and see how well the treatment can control the lymphoma in the brain/spinal fluid.
Phoenix, ArizonaAges 18 years+ - NCT03537482RecruitingEarly Phase 1
Testing a new drug for blood cancers in adults
This early trial studies how safe and tolerable APG-2575 is, and how the drug moves through the body, in adults with certain relapsed or hard-to-treat blood cancers. It may help researchers learn whether the treatment could work better for people who have limited options.
Jacksonville, FloridaAges 18 years+ - NCT03557619RecruitingPhase 1
Venetoclax test in women with specific non-Hodgkin lymphomas
This Phase 1 study tests how venetoclax affects certain hormone pills (ethinyl estradiol and levonorgestrel) in women with different non-Hodgkin lymphomas. It’s mainly looking at safety and drug interactions, which could help guide treatment for people who need hormone-based contraception.
Detroit, MichiganAges 18 years+ - NCT03838926RecruitingPhase 1
Testing how safe and tolerable a new drug is for blood cancers
This Phase 1 study tests how safe and tolerable trichostatin A is in adults whose blood cancers have come back or did not respond to standard treatments. It may help researchers find an effective dose while monitoring side effects closely.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04901702RecruitingPhase 1/Phase 2
Onivyde plus talazoparib or temozolomide for resistant solid tumors
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Palo Alto, CaliforniaAges 1–30 - NCT05270096Recruiting
Matches children and young people to leukemia treatment plans
This trial is set up to review tumor lab test results to help doctors choose the most appropriate next treatment for people with leukemia that has returned or did not respond. It mainly matters for younger patients who are not already on a standard treatment path.
GhentAges birth–25 years - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Los Angeles, CaliforniaAges 1–21 - NCT05713214Recruiting
Long-term follow-up after a gene-modified cell treatment
This study checks long-term health after receiving a gene-modified cell therapy through a St. Jude study. It helps doctors understand the treatment’s lasting effects and safety over time.
Memphis, TennesseeAges Any age - NCT05887167RecruitingPhase 1
Test safety of making CAR T cells from your own blood
This Phase 1 study looks at whether it is safe and practical to collect your own stem cells and use them to support CAR T-cell therapy for certain blood cancers that have come back or did not respond. It aims to find the best way to combine these steps, which may help some people receive CAR T treatment.
Los Angeles, CaliforniaAges 18–85 - NCT06252298RecruitingPhase 1
Testing a new drug for CD38-positive blood cancers
This trial tests a new drug, SCTC21C, for people with certain blood cancers (like myeloma or lymphoma) that have come back or not responded to other treatments. The goal is to see if the drug is safe and can help control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06326463RecruitingPhase 1
CAR T-cell therapy for CD70-positive blood cancers in children
This trial tests a special immune cell therapy (CAR T-cells) that targets a protein called CD70 on blood cancer cells. It is for children and young adults up to age 21 whose cancer has come back or hasn't gotten better with other treatments.
Memphis, TennesseeAges Up to 21 years - NCT06550102Recruiting
Drug response profiling for blood cancers
This study collects tumor samples from children and young adults with blood cancers to test how their cancer responds to different drugs. The goal is to find more effective treatments for each person.
Zurich, Canton of ZurichAges Up to 40 years - NCT07173595RecruitingPhase 1
QLS2309 for CD70-positive blood cancers that returned
This trial tests a new drug called QLS2309 for people with certain blood cancers that have come back or not responded to other treatments. The drug targets a protein called CD70 on the cancer cells, and this study aims to find the safest dose.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07255898RecruitingPhase 1
Study of BL-M24D1 for multiple myeloma and other blood cancers
This trial tests a new drug, BL-M24D1, for people with multiple myeloma or other blood cancers that have come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
Chengdu, SichuanAges 18 years+ - NCT06812104RecruitingPhase 1
A trial of KK2845 for certain blood cancers
This trial is testing a new drug, KK2845, for people with certain blood cancers that have come back or not responded to treatment. It focuses on acute myeloid leukemia (AML) and other blood cancers.
Kamogawa, ChibaAges 18 years+ - NCT07172191Enrolling by invitation
Fecal transplant for adults with blood cancer and infections
This trial tests whether transplanting healthy donor bacteria (fecal microbiota) into the gut can help adults with blood cancers who have stubborn infections, C. diff, or complications after stem cell transplant. It may reduce dangerous germs and improve gut health.
Budapest, BudapestAges Any age - NCT05470491RecruitingPhase 1/Phase 2
Haploidentical bone marrow transplant with GVHD prevention drugs
This trial tests a reduced-intensity bone marrow transplant from a related donor (haploidentical), using medicines to help prevent a serious complication called GVHD. It is for people with certain blood cancers and aims to improve outcomes by balancing transplant benefit with lower treatment intensity.
Bethesda, MarylandAges 12–120 - NCT05528887RecruitingPhase 1
CAR-T therapy study for relapsed or treatment-resistant blood cancers
This Phase 1 trial tests CAR-T cell therapy (immune cells modified to target cancer) in people whose blood cancers came back or didn’t respond to standard treatments. If you qualify, the study aims to see whether this treatment can fight the cancer and how safe it is.
Ningbo, ZhejiangAges 18–75 - NCT07131254RecruitingEarly Phase 1
Study of GT719 cell therapy for CD19-positive leukemia or lymphoma
This study is testing a new cell therapy called GT719 for people with B-cell leukemia or lymphoma that has not responded to standard treatments. The therapy targets a protein called CD19 on cancer cells, aiming to kill them.
Ganzhou, JiangxiAges 18–75
Hear when a new Refractory Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory hematologic malignancy?
- Yes. Clin2 currently lists 123 recruiting refractory hematologic malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory hematologic malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory hematologic malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.